CTLA4 and hepatocellular carcinoma: Presently, different cure solutions of HCC are clinically used for advanced HCC and other cancers, and immunotherapy has more and more concentrated on PD-1 and CTLA-4 monoclonal antibodies which stop the ICI pathway (Yeo et al., 2005).